浙江华海药业股份有限公司 关于获得药品注册证书的公告

Core Points - The company has received the drug registration certificate for Carbetocin Sodium Injection from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - Carbetocin Sodium Injection is indicated for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology, with significant efficacy in the urinary system [2][4] - The company has invested approximately RMB 7.12 million in the research and development of Carbetocin Sodium Injection [3] Drug Information - Drug Name: Carbetocin Sodium Injection - Dosage Form: Injection - Specification: 5ml: 25mg - Registration Category: Class 3 Chemical Drug - Approval Number: National Drug Approval No. H20255532 [1][2] Market Impact - The approval of Carbetocin Sodium Injection enhances the company's product line and market competitiveness, contributing positively to its business development [4] - The domestic market sales forecast for Carbetocin Sodium Injection in 2024 is approximately RMB 250 million [2]